SCHEDULE: Vanguard Reports 0% Stake in Enanta Pharmaceuticals

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Enanta Pharmaceuticals Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 6 to Schedule 13G concerning its beneficial ownership in Enanta Pharmaceuticals Inc.
• As of March 13, 2026, The Vanguard Group reported 0% beneficial ownership of Enanta Pharmaceuticals Inc. common stock.
• This change is a result of an internal realignment within The Vanguard Group that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for Enanta Pharmaceuticals. It reflects a procedural change in how Vanguard reports its holdings, not a change in investment strategy or a divestment from Enanta.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that large institutional investors like The Vanguard Group frequently undergo internal restructurings or realignments of their reporting entities. This filing reflects a procedural change in how Vanguard reports its holdings, rather than a strategic divestment from Enanta Pharmaceuticals. It is common for such changes to result in the parent entity reporting 0% beneficial ownership while underlying funds or subsidiaries continue to hold shares, now reporting them separately.

Stakeholder Impact

• Shareholders of Enanta Pharmaceuticals should understand that this filing does not necessarily indicate a divestment by Vanguard-managed funds, but rather a change in reporting structure.
• The Vanguard Group's internal realignment primarily impacts its own internal reporting and compliance structure.

Next Steps

• Certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.

Key Dates

Recommendation

This filing is a routine administrative update from The Vanguard Group regarding its beneficial ownership reporting structure, not a change in its investment thesis or a divestment from Enanta Pharmaceuticals. Therefore, it provides no new fundamental information to warrant a change in investment recommendation for Enanta Pharmaceuticals.

Keywords

Enanta Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Ownership Change, Common Stock, Realignment